Chlorthalidone, the preferred diuretic for hypertension management per the 2017 American College of Cardiology/American Heart Association guideline, has demonstrated cardiovascular outcome benefits. The introduction of a 12.5-mg tablet, HemiClor, aligns with current recommendations and allows for more precise dose titration, supporting individualized treatment strategies. However, the therapy should be initiated at a lower dose to reduce adverse metabolic effects. HemiClor, indicated to lower blood pressure, aims to reduce the risk of cardiovascular events but is contraindicated in certain patients. Its availability is expected in May 2025.

Source: PRM Pharma